PlayOn11 - Where Fans Become Winners
Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unve...

BUSINESS NEWS April 06, 2026

Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.

4 views 0 likes 0 comments
The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.

Author: Fierce Pharma

Read Original Article

Related News

Top Categories